Source Porcine Brain Hydrolysate
Fraction Low-MW Neuropeptide Mixture
Class Biological Peptide Extract
Form Lyophilized Powder
Pathway
Pathway
Research Model
Cerebrolysin is a complex biological preparation derived from purified porcine brain proteins through enzymatic hydrolysis. The resulting mixture consists primarily of low-molecular-weight neuropeptide fragments and free amino acids, with the peptide fraction characterised by molecular weights below 10 kDa. It is studied as a research tool for investigating neurotrophic factor-like activity, neuroplasticity, and neuroprotective signalling pathways in in vitro models. Supplied by NexPept as a lyophilized powder for in vitro laboratory research use. This compound has not been authorized by Health Canada for any therapeutic, clinical, or human use.
Compound Profile
Source, composition, fraction characterisation, analytical data
Source, composition, fraction characterisation, analytical data
| Property | Value |
|---|---|
| Source Material | Purified porcine brain proteins — enzymatic hydrolysate |
| Composition | Low-molecular-weight neuropeptide fragments (~25%) and free amino acids (~75%) |
| Peptide Fraction | Fragments with molecular weight <10 kDa; no single sequence or CAS applies |
| Neurotrophic Activity | BDNF-like, NGF-like, CNTF-like, and GDNF-like activity studied in vitro |
| Compound Class | Complex biological peptide extract — multicomponent neuropeptide mixture |
| Research Pathways | TrkB/BDNF, TrkA/NGF, MAPK/ERK, PI3K/Akt neuronal survival signalling |
| Physical Form | Lyophilized powder |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + protein/peptide characterisation |
| Appearance | White to off-white lyophilized solid |
In Vitro Research Context
Neurotrophic pathway pharmacology — laboratory use only
Neurotrophic pathway pharmacology — laboratory use only
Brain-derived neurotrophic factor pathway — neuroplasticity and synaptogenesis research
Nerve growth factor pathway — cholinergic neuron survival signalling studies
Downstream neuronal survival and anti-apoptotic signalling cascade research
Cerebrolysin is studied in preclinical in vitro settings as a multicomponent pharmacological tool for investigating neurotrophic factor-like signalling, neuroplasticity, and neuroprotective mechanisms. The preparation’s peptide fraction has been characterised for BDNF-like and NGF-like activity in neuronal cell culture models, with research applications including neurite outgrowth assays, TrkB/TrkA receptor activation studies, downstream MAPK/ERK and PI3K/Akt pathway analysis, and oxidative stress protection models. As a complex biological extract, Cerebrolysin is used in controlled laboratory environments to study the combined effects of low-molecular-weight neuropeptide mixtures on neuronal biology.
Available Formats
60mg — lyophilized powder
60mg — lyophilized powder
| Format | Net Quantity | Physical Form |
|---|---|---|
| Cerebrolysin 60mg | 60 mg / vial | Lyophilized powder |
Laboratory Storage
Controlled storage conditions for lyophilized material
Controlled storage conditions for lyophilized material
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture. Handling conditions should be established by qualified research personnel in accordance with the specific experimental protocol.
Research Literature
Scientific references & related resources
Scientific references & related resources
PubMed — Cerebrolysin Neurotrophic Research — peer-reviewed scientific literature on this preparation
PubMed — Cerebrolysin BDNF/NGF Pathway Studies — neurotrophic factor signalling and neuroprotection literature
Research Peptides in Canada — sourcing and research context for Canadian laboratories
What Are Research Peptides? — peptide classification and in vitro research context
This product is supplied exclusively for in vitro laboratory and non-clinical research use by qualified research personnel. It is not authorized by Health Canada for human or veterinary use. No therapeutic, clinical, or health claims are made.
This material must not be administered to humans or animals. No dosage, preparation, reconstitution, or administration instructions are provided or implied. All handling and use must be conducted by qualified personnel in accordance with applicable institutional policies and legal requirements.
Be the first to review “CEREBROLYSIN 60MG”
Related products
Reviews
There are no reviews yet.